Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | STAT3 | P40763 | 2/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576792 | 0.89 | ALDH1A1 (0.67) | KDM4EALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL1004449 | 0.89 | KDM4E (0.69) | KDM4EALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL9065484 | 0.87 | KDM4E (0.48) | KDM4EALDH1A1ALOX5STAT3NFE2L2 | |
| SCHEMBL15553080 | 0.86 | KDM4E (0.75) | KDM4EALDH1A1ALOX5PTGS1L3MBTL1 | |
| SCHEMBL8996063 | 0.85 | KDM4E (0.47) | KDM4EALDH1A1ALOX5STAT3NFE2L2 | |
| SCHEMBL403220 | 0.83 | KDM4E (0.61) | KDM4EALDH1A1ALOX5PTGS1L3MBTL1 | |
| SCHEMBL1515859 | 0.83 | TUBB1 (0.52) | KDM4EALDH1A1L3MBTL1TUBB1CYP1A2 | |
| SCHEMBL8585914 | 0.83 | KDM4E (0.66) | KDM4EALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL1527149 | 0.83 | KDM4E (0.61) | KDM4EALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL564282 | 0.82 | ALOX5 (0.66) | ALDH1A1ALOX5STAT3NFE2L2PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9283229-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150224107-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2015-08-13 | — | — | US | disclosed |
| US-9067893-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140235640-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8741915-B2 | Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20120208817-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2480086-A1 | NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011038204-A1 | NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235640-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | KDM4E 3194/4885ALDH1A1 207/4885ALOX5 682/4885 |
| US-20120208817-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | KDM4E 3194/4885ALDH1A1 207/4885ALOX5 682/4885 |
| US-20150224107-A1 | Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors | QDPR, GSR, CBR1 | KDM4E 3194/4885ALDH1A1 207/4885ALOX5 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.